MPT WWW
Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.

Commentary

BACK TO SANITY ON COX-2 DRUGS ; PATIENTS, DOCTORS CAN WEIGH RISK, REWARDS
Rocky Mountain News, 2-28-05

The Rocky Mountain News lauds the FDA advisory panelsí decision to keep Cox-2 drugs on the market, a gain ďfor people who need chronic pain management versus pain for the trial lawyers who hoped to litigate the pharmaceutical industry into oblivion. Itís about time the nationís months- long panic over Cox-2s came to an end. While the panelís decision helps restore sanity to the market for future drug development, far more important is its recognition that those drugs have huge benefits and that their risks should be weighed by doctors and patients.Ē

We concur. Some critics, unable to dispute the science behind this decision, have chosen instead to attack the FDA and its advisory boards as hopelessly corrupt - which also happens to benefit the trial lawyers who need to cast the FDA and its advisors as industry shills if they are to have any hope of creating a multi-billion dollar payday from the Vioxx debacle.

This tactic is misleading and does a disservice to the patients who depend on these drugs for relief from unremitting pain.



Project FDA.
  
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000
mpt@manhattan-institute.org